263 related articles for article (PubMed ID: 29601433)
1. Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.
Serpico MR; Maltz R; Crandall W; Bricker J; Dotson JL; Kim SC; Boyle B
J Pediatr Gastroenterol Nutr; 2018 Sep; 67(3):341-345. PubMed ID: 29601433
[TBL] [Abstract][Full Text] [Related]
2. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease.
Rahhal RM; Bishop WP
Inflamm Bowel Dis; 2008 Dec; 14(12):1678-82. PubMed ID: 18521913
[TBL] [Abstract][Full Text] [Related]
3. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Hoentjen F; Seinen ML; Hanauer SB; de Boer NK; Rubin DT; Bouma G; Harrell LE; van Bodegraven AA
Inflamm Bowel Dis; 2013 Feb; 19(2):363-9. PubMed ID: 22605661
[TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: efficacy, safety and dosage of adjunctive allopurinol in azathioprine/mercaptopurine nonresponders (AAA Study).
Friedman AB; Brown SJ; Bampton P; Barclay ML; Chung A; Macrae FA; McKenzie J; Reynolds J; Gibson PR; Hanauer SB; Sparrow MP
Aliment Pharmacol Ther; 2018 Apr; 47(8):1092-1102. PubMed ID: 29468701
[TBL] [Abstract][Full Text] [Related]
5. Optimizing Thiopurine Therapy in Inflammatory Bowel Disease Among 2 Real-life Intercept Cohorts: Effect of Allopurinol Comedication?
Meijer B; Seinen ML; van Egmond R; Bouma G; Mulder CJJ; van Bodegraven AA; de Boer NKH
Inflamm Bowel Dis; 2017 Nov; 23(11):2011-2017. PubMed ID: 28617756
[TBL] [Abstract][Full Text] [Related]
6. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD.
Govani SM; Higgins PD
J Crohns Colitis; 2010 Oct; 4(4):444-9. PubMed ID: 21122542
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.
Ansari A; Elliott T; Baburajan B; Mayhead P; O'Donohue J; Chocair P; Sanderson J; Duley J
Aliment Pharmacol Ther; 2008 Sep; 28(6):734-41. PubMed ID: 19145729
[TBL] [Abstract][Full Text] [Related]
8. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
Wall GC; Muktar H; Effken C; Mahajan PB
Pharmacotherapy; 2018 Feb; 38(2):259-270. PubMed ID: 29197117
[TBL] [Abstract][Full Text] [Related]
9. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
Smith MA; Blaker P; Marinaki AM; Anderson SH; Irving PM; Sanderson JD
J Crohns Colitis; 2012 Oct; 6(9):905-12. PubMed ID: 22386736
[TBL] [Abstract][Full Text] [Related]
10. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease.
Vasudevan A; Beswick L; Friedman AB; Moltzen A; Haridy J; Raghunath A; Sparrow M; van Langenberg D
Dig Liver Dis; 2018 Jul; 50(7):682-688. PubMed ID: 29525182
[TBL] [Abstract][Full Text] [Related]
11. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Lim WC; Reddy SI; Cao D; Hanauer SB
Aliment Pharmacol Ther; 2005 Sep; 22(5):441-6. PubMed ID: 16128682
[TBL] [Abstract][Full Text] [Related]
12. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2014 May; 176(22):. PubMed ID: 25352005
[TBL] [Abstract][Full Text] [Related]
13. Successful Pregnancies with Thiopurine-Allopurinol Co-Therapy for Inflammatory Bowel Disease.
Sheikh M; Nelson-Piercy C; Duley J; Florin T; Ansari A
J Crohns Colitis; 2015 Aug; 9(8):680-4. PubMed ID: 25939351
[TBL] [Abstract][Full Text] [Related]
14. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari A; Patel N; Sanderson J; O'Donohue J; Duley JA; Florin TH
Aliment Pharmacol Ther; 2010 Mar; 31(6):640-7. PubMed ID: 20015102
[TBL] [Abstract][Full Text] [Related]
15. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Sparrow MP; Hande SA; Friedman S; Cao D; Hanauer SB
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):209-14. PubMed ID: 17296529
[TBL] [Abstract][Full Text] [Related]
16. Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
Kreijne JE; de Veer RC; de Boer NK; Dijkstra G; West R; Moorsel SAW; de Jong DJ; van der Woude CJ; de Vries AC;
Aliment Pharmacol Ther; 2019 Aug; 50(4):407-415. PubMed ID: 31359480
[TBL] [Abstract][Full Text] [Related]
17. Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.
Curkovic I; Rentsch KM; Frei P; Fried M; Rogler G; Kullak-Ublick GA; Jetter A
Eur J Clin Pharmacol; 2013 Aug; 69(8):1521-31. PubMed ID: 23588559
[TBL] [Abstract][Full Text] [Related]
18. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.
Bradford K; Shih DQ
World J Gastroenterol; 2011 Oct; 17(37):4166-73. PubMed ID: 22072847
[TBL] [Abstract][Full Text] [Related]
19. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Leong RW; Gearry RB; Sparrow MP
Expert Opin Drug Saf; 2008 Sep; 7(5):607-16. PubMed ID: 18759713
[TBL] [Abstract][Full Text] [Related]
20. The role of thiopurine metabolite monitoring in inflammatory bowel disease.
Beswick L; Friedman AB; Sparrow MP
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):383-92. PubMed ID: 24684593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
